NASDAQ:IMVT

Immunovant Stock Forecast, Price & News

$15.48
+0.21 (+1.38 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.12
Now: $15.48
$15.49
50-Day Range
$13.08
MA: $15.92
$17.17
52-Week Range
$11.80
Now: $15.48
$53.75
Volume424,517 shs
Average Volume1.50 million shs
Market Capitalization$1.52 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Immunovant logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMVT
CUSIPN/A
CIKN/A
Phone917-580-3099
Employees42
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.45 per share

Profitability

Net Income$-66,390,000.00

Miscellaneous

Market Cap$1.52 billion
Next Earnings Date7/5/2021 (Estimated)
OptionableNot Optionable

Headlines

Is IMVT Stock A Buy or Sell? - Yahoo Finance
April 8, 2021 |  finance.yahoo.com
Is IMVT Stock A Buy or Sell?
April 8, 2021 |  finance.yahoo.com
Immunovant (NASDAQ:IMVT) Shares Gap Up to $15.64
April 7, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.80 out of 5 stars

Medical Sector

152nd out of 2,019 stocks

Biological Products, Except Diagnostic Industry

20th out of 177 stocks

Analyst Opinion: 4.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$15.48
+0.21 (+1.38 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMVT News and Ratings via Email

Sign-up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Immunovant (NASDAQ:IMVT) Frequently Asked Questions

Is Immunovant a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Immunovant stock.
View analyst ratings for Immunovant
or view top-rated stocks.

What stocks does MarketBeat like better than Immunovant?

Wall Street analysts have given Immunovant a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immunovant wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Immunovant?

Immunovant saw a increase in short interest in March. As of March 31st, there was short interest totaling 6,450,000 shares, an increase of 41.1% from the March 15th total of 4,570,000 shares. Based on an average daily volume of 1,570,000 shares, the days-to-cover ratio is presently 4.1 days. Currently, 15.9% of the company's stock are short sold.
View Immunovant's Short Interest
.

When is Immunovant's next earnings date?

Immunovant is scheduled to release its next quarterly earnings announcement on Monday, July 5th 2021.
View our earnings forecast for Immunovant
.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) released its quarterly earnings results on Tuesday, February, 16th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.07.
View Immunovant's earnings history
.

How has Immunovant's stock price been impacted by COVID-19?

Immunovant's stock was trading at $14.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IMVT stock has increased by 9.5% and is now trading at $15.48.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for IMVT?

15 equities research analysts have issued 1-year target prices for Immunovant's shares. Their forecasts range from $28.00 to $64.00. On average, they anticipate Immunovant's share price to reach $45.60 in the next year. This suggests a possible upside of 194.6% from the stock's current price.
View analysts' price targets for Immunovant
or view top-rated stocks among Wall Street analysts.

Who are Immunovant's key executives?

Immunovant's management team includes the following people:
  • Dr. Peter Salzmann M.B.A., M.D., CEO & Director (Age 54, Pay $1.09M)
  • Ms. Pamela Yanchik Connealy M.B.A., Chief Financial Officer (Age 59, Pay $544.84k)
  • Dr. Julia G. Butchko Ph.D., Chief Devel. & Technology Officer (Age 50)
  • Dr. Michael J. Elliott MBBS, Ph.D., Chief Scientific Officer (Age 62)
  • Ms. Lauren Schrier M.B.A., VP of Marketing
  • Ms. Beverly Paperiello, Sr. VP of Program Strategy, Chief Medical Officer & Chief of Staff
  • Dr. Alan Jacobs M.D., VP & Head of Neurology Devel.
  • Dr. Ann M. Daus, VP & Head of Global Quality
  • Dr. Rita Jain, Chief Medical Officer (Age 57)

Who are some of Immunovant's key competitors?

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include salesforce.com (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), The Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

What is Immunovant's stock symbol?

Immunovant trades on the NASDAQ under the ticker symbol "IMVT."

Who are Immunovant's major shareholders?

Immunovant's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Immunovant stock include Julia G Butchko and Sciences Ltd Roivant.
View institutional ownership trends for Immunovant
.

Which institutional investors are buying Immunovant stock?

IMVT stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Immunovant stock in the last two years include Julia G Butchko, and Sciences Ltd Roivant.
View insider buying and selling activity for Immunovant
or or view top insider-buying stocks.

How do I buy shares of Immunovant?

Shares of IMVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunovant's stock price today?

One share of IMVT stock can currently be purchased for approximately $15.48.

How much money does Immunovant make?

Immunovant has a market capitalization of $1.52 billion. The company earns $-66,390,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

How many employees does Immunovant have?

Immunovant employs 42 workers across the globe.

What is Immunovant's official website?

The official website for Immunovant is www.immunovant.com.

Where are Immunovant's headquarters?

Immunovant is headquartered at 320 WEST 37TH STREET, NEW YORK NY, 10018.

How can I contact Immunovant?

Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The company can be reached via phone at 917-580-3099.


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.